Tvardi Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $65 price target The firm sees an “underappreciated opportunity” for the company’s lead asset TTI-101, a first-in-class STAT3 inhibitor, in idiopathic pulmonary fibrosis and hepatocellular carcinoma. The analyst forecasts $1.2B peak risk-adjusted sales in 2040. The blinded Phase 2a interim data suggest that TTI-101 could reverse idiopathic pulmonary fibrosis progression, thus supporting favorable differentiation from key competitors, with detailed Phase 2a results expected in the second half of 2025 “serving as a potential valuable inflection point,” the analyst tells investors in a research note.